BRSV (Bovine Respiratory Syncytial Virus)

Bovine Respiratory Syncytial Virus (BRSV) vaccine is a critical immunization product designed to protect cattle against respiratory disease caused by BRSV, one of the most significant viral pathogens contributing to the bovine respiratory disease (BRD) complex. BRSV infection causes severe lower respiratory tract disease characterized by bronchiolitis and interstitial pneumonia, particularly devastating in young calves during their first year of life. The virus belongs to the Pneumoviridae family and is closely related to human respiratory syncytial virus, sharing similar pathogenic mechanisms and clinical presentations. Vaccination against BRSV represents an essential component of comprehensive BRD prevention programs in both beef and dairy operations.

The mechanism of action varies depending on vaccine type. Modified live virus (MLV) vaccines contain attenuated BRSV strains that replicate in the vaccinated animal, stimulating robust humoral and cell-mediated immune responses without causing clinical disease. Killed (inactivated) vaccines contain BRSV antigens that cannot replicate but stimulate antibody production when combined with adjuvants. Intranasal vaccines deliver antigens directly to the respiratory mucosa, inducing local mucosal immunity including secretory IgA antibodies at the site where natural infection occurs. Each vaccine type offers distinct advantages for different management scenarios and animal populations.

BRSV vaccines are available in multiple formulations including injectable modified live vaccines, killed adjuvanted vaccines, and intranasal products. Most commercial products combine BRSV with other respiratory pathogens including infectious bovine rhinotracheitis (IBR), bovine viral diarrhea (BVD), and parainfluenza-3 (PI3) in multivalent respiratory vaccine combinations. Standalone BRSV vaccines are less common but available for specific situations requiring targeted BRSV protection. Product selection depends on factors including animal age, pregnancy status, previous vaccination history, and the timing requirements of specific management situations.

Regulatory approval for BRSV vaccines covers cattle as the primary labeled species, with products licensed by the USDA Center for Veterinary Biologics. Both modified live and killed BRSV vaccines have established safety and efficacy records, though the optimal vaccine type for specific situations remains an area of ongoing research and veterinary discussion. The significance of BRSV in the BRD complex and its economic impact on cattle operations has driven continuous development of improved vaccines and vaccination strategies aimed at reducing respiratory disease losses in beef and dairy cattle populations.

The primary indication for BRSV vaccine is prevention of respiratory disease caused by bovine respiratory syncytial virus infection. BRSV is recognized as one of the most important viral contributors to the bovine respiratory disease complex, causing significant morbidity and mortality in cattle worldwide. The virus preferentially targets the lower respiratory tract, causing severe bronchiolitis and interstitial pneumonia that predisposes infected animals to secondary bacterial infections. Clinical signs range from mild respiratory distress to severe dyspnea, and mortality rates can be substantial in naive populations experiencing primary BRSV outbreaks.

Young calves represent the population at highest risk for severe BRSV disease, making vaccination of this age group a primary focus of prevention programs. Calves between one and six months of age are particularly susceptible to severe BRSV infection, though disease can occur at any age. Dairy calves in calf-raising facilities face substantial BRSV exposure risk due to close housing and stress factors. Beef calves experience peak susceptibility during the weaning period when stress-induced immunosuppression coincides with potential pathogen exposure. Vaccination timing must balance the need for early protection against the interference of maternal antibodies in very young animals.

Feedlot receiving programs routinely include BRSV vaccination as part of comprehensive respiratory disease prevention protocols. Cattle entering feedlots from diverse sources face multiple stressors including transport, commingling, dietary changes, and exposure to novel pathogens, creating conditions highly favorable for BRD development. BRSV vaccination upon arrival, often combined with other respiratory antigens in multivalent products, aims to stimulate protective immunity during this high-risk period. The choice between modified live and killed vaccines in feedlot settings depends on timing constraints, concurrent treatments, and individual operation protocols.

Cow-calf operations utilize BRSV vaccination in breeding herd management and calf preconditioning programs. Pre-breeding vaccination of cows ensures maternal immunity and optimal colostral antibody transfer to newborn calves. Preconditioning programs that include BRSV vaccination prior to weaning and sale prepare calves immunologically for the challenges of marketing and feedlot entry. Some operations practice vaccination of pregnant cows to boost fetal immune system priming through transplacental antibody transfer, though this approach requires appropriate vaccine selection for use in pregnant animals.

Dairy operations face unique BRSV challenges related to their intensive management systems and year-round calving patterns. Continuous introduction of susceptible calves into potentially contaminated environments maintains endemic BRSV circulation in many dairy systems. Vaccination programs for dairy replacements should begin early in life using products appropriate for young calves, with booster doses timed to maintain protection through the high-risk first year. Adult dairy cattle vaccination contributes to herd immunity and reduces viral shedding that exposes susceptible calves.

Dosage and administration protocols for BRSV vaccines vary significantly depending on the specific product type, with modified live, killed, and intranasal vaccines each having distinct requirements. Injectable modified live BRSV vaccines typically require a single 2 mL dose administered subcutaneously or intramuscularly, depending on product labeling. These vaccines may provide protection with a single dose in some situations, though two-dose primary series are often recommended, particularly for calves with potential maternal antibody interference. Product-specific label directions should always guide dosing decisions.

Killed BRSV vaccines universally require two-dose primary vaccination series administered two to four weeks apart, as inactivated antigens without adjuvant-enhanced presentation do not stimulate adequate immunity from a single exposure. The standard dose for most killed BRSV products is 2 mL or 5 mL depending on the specific formulation and adjuvant system. Subcutaneous administration in the neck region is typically specified. The two-dose requirement for killed vaccines must be emphasized to producers, as single-dose administration provides inadequate protection and false confidence.

Intranasal BRSV vaccines represent a distinct administration category designed to stimulate mucosal immunity directly at the respiratory tract portal of entry. Products like Inforce 3 deliver attenuated BRSV along with IBR and PI3 antigens via nasal spray, requiring 1 mL per nostril for a total 2 mL dose. Intranasal administration bypasses maternal antibody interference, allowing effective vaccination of very young calves. These products also provide rapid onset of immunity, making them valuable for situations requiring quick protection such as feedlot arrival or outbreak response.

Primary vaccination timing depends on the target population and management system. For beef calves, initial BRSV vaccination is commonly administered at two to four months of age during routine processing, with booster doses at weaning. Dairy calves may be vaccinated earlier using intranasal products that overcome maternal antibody interference. Feedlot cattle typically receive vaccination upon arrival, with product selection based on timing constraints and concurrent processing procedures. Pregnant cattle should receive only products labeled safe for use during pregnancy.

Annual revaccination is generally recommended to maintain protective immunity, though the optimal frequency and timing of boosters remains an area of ongoing research. Pre-breeding vaccination of cows approximately four to six weeks before calving enhances colostral antibody levels for passive protection of newborn calves. Preconditioning programs typically include BRSV vaccination two to four weeks before weaning and sale to allow immunity development before marketing stress. Feedlot revaccination protocols vary by operation based on length of feeding period and observed disease pressure.

Withdrawal times for BRSV vaccines are generally minimal, with most products specifying 21 days before slaughter. Modified live vaccines may have additional label restrictions regarding use in pregnant animals or concurrent administration with certain other products. There are typically no milk discard requirements for dairy cattle. Accurate record keeping of vaccination dates, products, lot numbers, and withdrawal times supports compliance with quality assurance programs and facilitates disease investigation if respiratory problems occur despite vaccination.

BRSV vaccines are generally well-tolerated by cattle, though adverse effects vary somewhat by vaccine type. Modified live BRSV vaccines may cause transient mild respiratory signs in some vaccinated animals, reflecting the limited replication of attenuated vaccine virus in respiratory tissues. These vaccine-associated respiratory signs are typically mild and self-limiting, consisting of slight nasal discharge or occasional coughing for one to three days post-vaccination. Such reactions should be distinguished from more severe respiratory disease that might indicate concurrent infection or vaccine failure.

Injection site reactions are common following administration of killed BRSV vaccines, which contain adjuvants necessary for enhancing immune response to inactivated antigens. Localized swelling at the injection site may range from barely perceptible to moderately prominent, typically developing within 24 to 72 hours and gradually resolving over one to four weeks. These reactions represent normal inflammatory responses to adjuvant components. Subcutaneous administration in the neck region, as labeled, minimizes potential economic impact from injection site lesions compared to administration in higher-value carcass areas.

Transient systemic reactions following BRSV vaccination include mild fever, decreased appetite, reduced activity, and general malaise lasting one to two days. These nonspecific signs reflect immune system activation in response to vaccine antigens. Young calves and animals receiving their first vaccination may show more pronounced systemic responses. Minimizing concurrent stressors around the time of vaccination helps reduce the impact of these temporary effects on animal performance and well-being.

Intranasal BRSV vaccines may cause local nasal irritation and transient increased nasal discharge following administration. Some animals exhibit sneezing, head shaking, or mild nasal discomfort immediately after intranasal vaccine delivery. These effects are typically brief and resolve within hours. Rarely, more pronounced respiratory signs may develop in animals with pre-existing subclinical respiratory infection or immune compromise, as vaccine virus replication may be enhanced in already-compromised respiratory tissues.

Anaphylactic reactions to BRSV vaccines are rare but can occur, particularly with killed adjuvanted products. Signs of anaphylaxis include sudden collapse, respiratory distress, facial swelling, urticaria, and cardiovascular shock, typically occurring within minutes of administration. Immediate treatment with epinephrine is essential, and emergency medications should be readily available during vaccination procedures. Animals experiencing anaphylaxis should not receive future doses of the same product without veterinary consultation regarding alternative formulations.

The primary contraindication for modified live BRSV vaccines is administration to pregnant cattle, as attenuated vaccine virus replication may theoretically pose risks to fetal development or pregnancy maintenance. Most MLV respiratory vaccine labels specifically contraindicate use in pregnant animals, particularly during early gestation. However, some modified live BRSV products have been tested and approved for use in pregnant cattle, so product-specific labeling must be consulted. When vaccination of pregnant animals is necessary, killed BRSV vaccines or products specifically labeled for pregnant cattle should be selected.

Vaccination of clinically ill animals is contraindicated because concurrent disease compromises immune function and prevents adequate response to vaccine antigens. Animals with active respiratory disease, fever, or other illness should have vaccination deferred until recovery. Vaccinating during clinical illness may also exacerbate disease severity if modified live vaccines replicate more extensively in compromised respiratory tissues. The physiological stress of mounting an immune response adds burden to animals already fighting infection.

Severely stressed animals from recent transport, commingling, or major environmental changes present a relative contraindication for BRSV vaccination, as stress-induced immunosuppression impairs vaccine response. However, practical constraints often necessitate vaccination during high-stress periods such as feedlot arrival when disease risk is also elevated. In these situations, intranasal vaccines may offer advantages by bypassing systemic immunosuppression and providing rapid mucosal protection. The balance between stress effects and disease prevention must be evaluated for each situation.

Animals with documented history of severe hypersensitivity or anaphylactic reaction to previous BRSV vaccination should not receive the same product. Alternative products from different manufacturers or with different formulations may be considered under veterinary guidance, though cross-reactivity cannot be excluded. Very young calves with high levels of circulating maternal antibodies may not respond adequately to some BRSV vaccines, as passive antibodies neutralize vaccine antigens before they can stimulate active immunity. Intranasal vaccines partially overcome this limitation through mucosal delivery.

BRSV vaccines may be administered concurrently with other commonly used cattle vaccines when given at separate injection sites. Multivalent respiratory vaccines combining BRSV with IBR, BVD, and PI3 antigens represent the most common approach to respiratory disease prevention, providing comprehensive protection with single-product convenience. When using separate products to build respiratory protection, simultaneous administration at different anatomical locations is acceptable and widely practiced. Maintaining adequate separation between injection sites allows independent immune response development.

Concurrent administration of modified live BRSV vaccines with clostridial bacterin-toxoid products is routine practice in cattle processing protocols. Research generally supports acceptable immune responses when viral and bacterial vaccines are administered simultaneously at separate sites. Some evidence suggests that the inflammatory response to bacterin products may transiently affect viral vaccine virus replication, leading some veterinarians to recommend spacing administration by one to two weeks when practical. However, simultaneous administration remains standard practice for most operations.

Antibiotic administration concurrent with BRSV vaccination requires consideration of the vaccine type being used. Modified live BRSV vaccines are not directly affected by antibiotics since vaccine efficacy depends on viral replication rather than bacterial components. However, animals requiring antibiotic treatment are typically ill, and the underlying disease condition may impair immune responses more significantly than the antibiotic therapy itself. Killed BRSV vaccines are similarly unaffected by concurrent antibiotic administration.

Immunosuppressive medications including corticosteroids can impair immune response development following BRSV vaccination. Animals receiving systemic corticosteroid therapy may not develop adequate protective immunity and may require revaccination after drug withdrawal. This interaction is particularly relevant for feedlot medicine where corticosteroids are sometimes used in treatment protocols for sick cattle. Documentation of immunosuppressive drug use helps guide appropriate revaccination decisions. Non-steroidal anti-inflammatory drugs have less impact on vaccine response than corticosteroids.

Modified live BRSV vaccine precautions include restrictions on use in pregnant animals for most products. The attenuated vaccine virus retains ability to replicate in vaccinated animals, and this replication may theoretically affect fetal development or pregnancy maintenance. Always consult product labels for pregnancy safety information, as some modified live BRSV vaccines have been specifically tested and approved for use in pregnant cattle while others carry pregnancy contraindications. When in doubt, killed vaccines offer a safer alternative for pregnant animals.

Vaccine handling precautions are critical for maintaining potency, particularly for modified live BRSV vaccines that contain living attenuated organisms. These products must be stored frozen or lyophilized under refrigeration until reconstitution, then used within the timeframe specified after mixing, typically one to two hours. Exposure to elevated temperatures rapidly inactivates modified live vaccines, potentially resulting in vaccination failure. Killed vaccines similarly require refrigeration but are more stable after temperature excursions than modified live products.

Human safety precautions apply to handling all BRSV vaccine types, though modified live products warrant additional attention. While BRSV does not cause disease in humans, accidental self-injection with adjuvanted killed vaccines can cause significant tissue reactions including pain, swelling, and potential abscess formation. Modified live vaccines theoretically present minimal zoonotic risk, but proper handling procedures should always be followed. Needle stick prevention through appropriate animal restraint and attention during injection procedures minimizes human exposure risk.

Vaccination timing relative to other stressors significantly impacts BRSV vaccine efficacy and should be carefully planned. Administering vaccines during peak stress periods may result in suboptimal immune responses, while vaccinating too close to anticipated pathogen exposure may not allow adequate time for immunity development. The balance between these competing considerations requires attention to specific operation timelines and disease pressure. Pre-conditioning programs that space vaccination appropriately before weaning stress exemplify optimal timing approaches.

Record keeping and quality assurance documentation should accompany all BRSV vaccination activities. Accurate records of vaccination dates, products used, lot numbers, routes of administration, and animal identification support both food safety compliance and disease investigation if respiratory problems occur despite vaccination. Participation in Beef Quality Assurance and similar programs requires documentation of vaccine administration details including injection sites and withdrawal times.

Storage requirements for BRSV vaccines vary significantly by product type, with modified live and killed formulations having distinct cold chain needs. Modified live BRSV vaccines are typically supplied as lyophilized (freeze-dried) pellets with separate diluent, requiring frozen storage at -4°F to -112°F (-20°C to -80°C) for some products or refrigerated storage at 35-45°F (2-7°C) for others. Product-specific storage requirements must be followed precisely, as improper storage rapidly inactivates the living attenuated organisms essential for vaccine efficacy. Temperature monitoring and documentation support quality assurance requirements.

Killed BRSV vaccines require refrigerated storage at 35-45°F (2-7°C) and must be protected from freezing, which damages adjuvant emulsions and protein antigens. These products are generally more stable than modified live vaccines but still require consistent cold chain maintenance throughout distribution and on-farm storage. Storage in dedicated refrigerators away from heat sources and with reliable temperature control ensures product integrity. Regular calibration and monitoring of refrigerator temperatures provides documentation of proper storage conditions.

Reconstitution of lyophilized modified live BRSV vaccines must follow manufacturer specifications exactly. The supplied diluent should be at proper temperature before mixing, and reconstitution should occur immediately before use. Once reconstituted, modified live vaccines typically must be used within one to two hours, as the attenuated virus rapidly loses viability in liquid suspension. Reconstituted vaccine should be protected from direct sunlight and temperature extremes during the administration period. Any remaining reconstituted vaccine must be discarded at the end of the session.

Multi-dose bottle handling for killed BRSV vaccines requires attention to aseptic technique to prevent contamination. Transfer needles should be used for withdrawing doses rather than repeated insertion of administration needles. Bottles should be shaken before each use to ensure uniform suspension of adjuvanted antigens. Once opened, multi-dose bottles should be used within the timeframe specified on the label, typically within a few hours under field conditions. Proper disposal of expired or compromised vaccines, used sharps, and empty containers follows standard protocols for biological waste.

All cattle breeds are susceptible to BRSV infection and benefit from vaccination, with no documented breed-specific differences in disease susceptibility or vaccine response. Beef breeds managed in extensive pasture systems may experience different BRSV exposure patterns than dairy breeds in intensive confinement, though both production types benefit from comprehensive respiratory vaccination programs. The stress of weaning, transport, and feedlot entry creates elevated BRSV risk for beef cattle regardless of breed, emphasizing the importance of pre-conditioning vaccination programs.

Dairy breed considerations for BRSV vaccination include the integration of respiratory vaccines into calf-raising protocols and heifer development programs. Holstein, Jersey, and other dairy calves raised in calf barns or hutches face substantial BRSV exposure risk from endemic viral circulation in intensive dairy systems. Early vaccination using intranasal products may be particularly valuable for dairy calves to overcome maternal antibody interference and establish mucosal immunity before significant pathogen exposure occurs. Adult dairy cattle vaccination contributes to herd immunity and reduces viral shedding.

Bos indicus cattle and their crosses may demonstrate some differences in immune response characteristics compared to Bos taurus breeds, though specific BRSV vaccine response differences have not been extensively characterized. Brahman-influenced cattle are widely used in southern United States beef operations where heat stress represents an additional challenge affecting immune function and disease susceptibility. Vaccination protocols for these populations should account for environmental stress factors that may influence vaccine response timing and efficacy.

Feedlot cattle represent a particularly important target population for BRSV vaccination regardless of breed composition. The commingling of cattle from diverse genetic backgrounds in feedlot settings creates opportunities for BRSV transmission between immunologically naive populations. Receiving vaccination protocols should address all incoming cattle equally, with product selection and timing based on practical constraints rather than breed-specific considerations. The universal susceptibility of cattle to BRSV means that comprehensive vaccination coverage provides the greatest herd-level protection.

Multivalent respiratory vaccines combining BRSV with IBR, BVD, and PI3 antigens represent the most commonly used products for comprehensive respiratory disease prevention in cattle. Five-way respiratory vaccines provide broad protection against the major viral contributors to BRD complex with single-product convenience. Both modified live and killed formulations of these combination products are available, with selection based on animal status, timing requirements, and management preferences. Brand options include Pyramid 5, Vista 5, Bovi-Shield Gold, Express 5, Triangle 5, and numerous other commercial products.

Intranasal respiratory vaccines like Inforce 3 and Nasalgen provide an alternative delivery route that offers unique advantages for certain situations. These products stimulate mucosal immunity directly at the respiratory tract portal of entry, provide rapid onset of protection, and overcome maternal antibody interference in young calves. Intranasal vaccines are particularly valuable for feedlot arrival situations requiring quick immunity development and for vaccination of calves too young to respond adequately to injectable products.

Bacterial respiratory vaccines targeting Mannheimia haemolytica and Pasteurella multocida address the secondary bacterial infections that commonly complicate viral BRD. These products complement rather than replace BRSV vaccination, as optimal BRD prevention requires protection against both viral and bacterial pathogens. Combination strategies using both viral and bacterial vaccines provide the most comprehensive approach to respiratory disease prevention in high-risk cattle populations. Some products combine viral and bacterial antigens in single formulations for added convenience.